BioSpace News Archive

Business

Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer

Dr. Heineman has over two decades of experience successfully leading clinical development programs and previously served as Oncolytics’ Global Head of Clinical Development and Operations.

December 21, 2021
·
5 min read
Business

Vipergen Establishes Research Partnership with Bayer to Discover Novel Compoundsfor Pharmaceuticals and More Sustainable Crop Protection Solutions

Vipergen announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions.

December 21, 2021
·
3 min read
Business

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

CytoSorbents Corporation announces the appointment of Professor Daniel Wendt , MD, PhD, MHBA, FETCS as Vice President, Medical Affairs Cardiovascular commencing January 1, 2022.

December 21, 2021
·
8 min read
FDA

ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg.

December 21, 2021
·
3 min read
Business

XVIVO accelerates their business in Brazil by signing a partnership contract with Contatti Medical

XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) By selling and distributing through Contatti Medical’s well-established network in Brazil, the XVIVO market access will increase significantly.

December 21, 2021
·
2 min read
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts

IMV Inc. today announced the finalization of the basket clinical study evaluating maveropepimut-S.

December 21, 2021
·
5 min read
Deals

FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections

In advance of the shareholder vote for the business combination between FS Development Corp. II (NASDAQ: FSII) and Pardes Biosciences, Inc. (“Pardes”), the CEOs of both companies are sharing their thoughts on the COVID-19 public health emergency and how they expect the combined company to play an important role in addressing one of the biggest health crises of our time.

December 21, 2021
·
11 min read
Deals

Mednow Enters into Agreement to Acquire Liver Care Canada Inc. and London Pharmacare Inc.

Mednow enters agreement to acquire London Pharmacare, increasing its specialty pharmacy services and expertise to include hepatology and the treatment of liver disease.

December 21, 2021
·
12 min read
Drug Development

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors

Repare Therapeutics Inc. today announced the first patient has been dosed in the Company’s Phase 1 clinical trial of RP-6306, a first-in-class small molecule candidate targeting PKMYT1, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors (NCT05147272) (the “MAGNETIC” trial).

December 21, 2021
·
2 min read
Business

Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz

Schrödinger today announced that Joel Lebowitz is retiring from his position as chief financial officer.

December 21, 2021
·
4 min read